

Specimen Collected: 8/17/2026 14:56 MDT

Targeted drug prof, Mass Spec/EMIT, UR	Received: 8/18/2026 15:43 MDT		Report/Verified: 8/18/2026 15:56 MDT
Procedure	Result	Units	Reference Interval
Creatinine,Urine	400.0	mg/dL	[20.0-400.0]
Targeted drug prof, Mass Spec/EMIT, UR	Received: 8/18/2026 15:43 MDT		Report/Verified: 8/18/2026 15:57 MDT
Procedure	Result	Units	Reference Interval
Barbiturates Screen,U	Negative ⁱ¹		
Cocaine Screen,U	Negative ⁱ²		
Carisoprodol Screen,U	Negative ⁱ³		
Ethyl Glucuronide Screen,U	Negative ⁱ⁴		
THC (Cannabinoids) Screen,U	Negative ⁱ⁵		
Phencyclidine Screen,U	Negative ⁱ⁶		
Tramadol Screen,U	Negative ⁱ⁷		
6-acetylmorphine,U	See Note ⁱ⁸		
7-Aminoclonazepam,U	See Note ⁱ⁹		
Alpha-OH-Alprazolam,U	See Note ⁱ¹⁰		
Alpha-OH-Midazolam,U	See Note ⁱ¹¹		
Alprazolam,U	See Note ⁱ¹²		
Amphetamine,U	See Note ⁱ¹³		
Buprenorphine,U	See Note ⁱ¹⁴		
Clonazepam,U	See Note ⁱ¹⁵		
Codeine,U	See Note ⁱ¹⁶		
Diazepam,U	See Note ⁱ¹⁷		
Fentanyl,U	See Note ⁱ¹⁸		
Gabapentin,U	See Note ⁱ¹⁹		
Hydrocodone,U	See Note ⁱ²⁰		
Hydromorphone,U	See Note ⁱ²¹		
Lorazepam,U	See Note ⁱ²²		
MDA,U	See Note ⁱ²³		
MDEA,U	See Note ⁱ²⁴		
MDMA,U	See Note ⁱ²⁵		
Meperidine metabolite,U	See Note ⁱ²⁶		
Methamphetamine,U	See Note ⁱ²⁷		
Methylphenidate,U	See Note ⁱ²⁸		
Midazolam,U	See Note ⁱ²⁹		
Morphine,U	See Note ⁱ³⁰		
Naloxone,U	See Note ⁱ³¹		
Norbuprenorphine,U	See Note ⁱ³²		
Nordiazepam,U	See Note ⁱ³³		
Norfentanyl,U	See Note ⁱ³⁴		
Norhydrocodone,U	See Note ⁱ³⁵		
Noroxycodone,U	See Note ⁱ³⁶		

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270**Report Request ID:** 21654081**Printed:** 8/27/2026 08:26 MDT

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 42 years Female

Targeted drug prof, Mass Spec/EMIT, UR	Received: 8/18/2026 15:43 MDT		Report/Verified: 8/18/2026 15:57 MDT
Procedure	Result	Units	Reference Interval
Noroxymorphone,U	See Note ⁱ³⁷		
Oxazepam,U	See Note ⁱ³⁸		
Oxycodone,U	See Note ⁱ³⁹		
Oxymorphone,U	See Note ⁱ⁴⁰		
Phentermine,U	See Note ⁱ⁴¹		
Pregabalin,U	See Note ⁱ⁴²		
Tapentadol,U	See Note ⁱ⁴³		
Tapentadol-o-Sulf,U	See Note ⁱ⁴⁴		
Temazepam,U	See Note ⁱ⁴⁵		
Zolpidem,U	See Note ⁱ⁴⁶		
Zolpidem Metabolite,U	See Note ⁱ⁴⁷		
Targeted Drug Profile Comment	See Note ⁱ⁴⁸		
EER Targeted Drug Profile,U	See Note ^{f1}		
Methadone Metabolite Screen,U	Negative ^{f2 i49}		

Result Footnote

f1: EER Targeted Drug Profile, U
Authorized individuals can access the ARUP Enhanced Report with an ARUP Connect account using the following link.

Your local lab can assist you in obtaining the patient report if you don't have a Connect account.

f2: Methadone Metabolite Screen, U

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

Test Information

i1: Barbiturates Screen, U
INTERPRETIVE INFORMATION: Barbiturates Screen, U

Positive Cutoff: 200 ng/mL

Methodology: Immunoassay

i2: Cocaine Screen, U
INTERPRETIVE INFORMATION: Cocaine Screen, U

Positive Cutoff: 150 ng/mL

Methodology: Immunoassay

i3: Carisoprodol Screen, U
INTERPRETIVE INFORMATION: Carisoprodol Screen, U

Positive Cutoff: 100 ng/mL

Methodology: Immunoassay

The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 2 of 8

Test Information

- i4: Ethyl Glucuronide Screen, U
INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen, U

Positive Cutoff: 500 ng/mL
Methodology: Immunoassay
- i5: THC (Cannabinoids) Screen, U
INTERPRETIVE INFORMATION: THC (Cannabinoids) Screen, U

Positive Cutoff: 50 ng/mL
Methodology: Immunoassay
- i6: Phencyclidine Screen, U
INTERPRETIVE INFORMATION: Phencyclidine Screen, U

Positive Cutoff: 25 ng/mL
Methodology: Immunoassay
- i7: Tramadol Screen, U
INTERPRETIVE INFORMATION: Tramadol Screen, U

Positive Cutoff: 100 ng/mL
Methodology: Immunoassay
- i8: 6-acetylmorphine, U
INTERPRETIVE INFORMATION: 6-acetylmorphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i9: 7-Aminoclonazepam, U
INTERPRETIVE INFORMATION: 7-Aminoclonazepam, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry
- i10: Alpha-OH-Alprazolam, U
INTERPRETIVE INFORMATION: Alpha-OH-Alprazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i11: Alpha-OH-Midazolam, U
INTERPRETIVE INFORMATION: Alpha-OH-Midazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i12: Alprazolam, U
INTERPRETIVE INFORMATION: Alprazolam, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 3 of 8

Test Information

- i13: Amphetamine, U
INTERPRETIVE INFORMATION: Amphetamine, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry
- i14: Buprenorphine, U
INTERPRETIVE INFORMATION: Buprenorphine, U

Positive Cutoff: 5 ng/mL
Methodology: Mass Spectrometry
- i15: Clonazepam, U
INTERPRETIVE INFORMATION: Clonazepam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i16: Codeine, U
INTERPRETIVE INFORMATION: Codeine, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry
- i17: Diazepam, U
INTERPRETIVE INFORMATION: Diazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry
- i18: Fentanyl, U
INTERPRETIVE INFORMATION: Fentanyl, U

Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry
- i19: Gabapentin, U
INTERPRETIVE INFORMATION: Gabapentin, U

Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry
- i20: Hydrocodone, U
INTERPRETIVE INFORMATION: Hydrocodone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry
- i21: Hydromorphone, U
INTERPRETIVE INFORMATION: Hydromorphone, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 4 of 8

Test Information

i22: Lorazepam, U
INTERPRETIVE INFORMATION:Lorazepam, U

Positive Cutoff: 60 ng/mL
Methodology: Mass Spectrometry

i23: MDA, U
INTERPRETIVE INFORMATION:MDA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i24: MDEA, U
INTERPRETIVE INFORMATION:MDEA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i25: MDMA, U
INTERPRETIVE INFORMATION:MDMA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i26: Meperidine metabolite, U
INTERPRETIVE INFORMATION:Meperidine metabolite, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i27: Methamphetamine, U
INTERPRETIVE INFORMATION:Methamphetamine, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i28: Methylphenidate, U
INTERPRETIVE INFORMATION:Methylphenidate, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i29: Midazolam, U
INTERPRETIVE INFORMATION:Midazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i30: Morphine, U
INTERPRETIVE INFORMATION:Morphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 5 of 8

Test Information

- i31: Naloxone, U
INTERPRETIVE INFORMATION:Naloxone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry
- i32: Norbuprenorphine, U
INTERPRETIVE INFORMATION:Norbuprenorphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry
- i33: Nordiazepam, U
INTERPRETIVE INFORMATION:Nordiazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry
- i34: Norfentanyl, U
INTERPRETIVE INFORMATION:Norfentanyl, U

Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry
- i35: Norhydrocodone, U
INTERPRETIVE INFORMATION:Norhydrocodone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry
- i36: Noroxycodone, U
INTERPRETIVE INFORMATION:Noroxycodone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry
- i37: Noroxymorphone, U
INTERPRETIVE INFORMATION:Noroxymorphone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry
- i38: Oxazepam, U
INTERPRETIVE INFORMATION:Oxazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry
- i39: Oxycodone, U
INTERPRETIVE INFORMATION:Oxycodone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 6 of 8

Test Information

i40: Oxymorphone, U
INTERPRETIVE INFORMATION: Oxymorphone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i41: Phentermine, U
INTERPRETIVE INFORMATION: Phentermine, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i42: Pregabalin, U
INTERPRETIVE INFORMATION: Pregabalin, U

Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

i43: Tapentadol, U
INTERPRETIVE INFORMATION: Tapentadol, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i44: Tapentadol-o-Sulf, U
INTERPRETIVE INFORMATION: Tapentadol-o-Sulf, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i45: Temazepam, U
INTERPRETIVE INFORMATION: Temazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i46: Zolpidem, U
INTERPRETIVE INFORMATION: Zolpidem, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i47: Zolpidem Metabolite, U
INTERPRETIVE INFORMATION: Zolpidem Metabolite, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i48: Targeted Drug Profile Comment
Flagging indicates a positive result; not that the result is abnormal.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 7 of 8

Test Information

i48: Targeted Drug Profile Comment
testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i49: Methadone Metabolite Screen, U
INTERPRETIVE INFORMATION: Methadone Metabolite Screen, U

Positive Cutoff: 100 ng/mL

Methodology: Immunoassay

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 26-229-900270

Report Request ID: 21654081

Printed: 8/27/2026 08:26 MDT

Page 8 of 8